Mekonos
Mekonos offers a chip technology to enable industrial scale genetic modification and cell editing in a safe, highly targeted, highly efficient and versatile manner. This technology is vital in the areas of cancer immunotherapy, gene engineering, and drug development.
Based based in San Francisco, California, US, Mekonos works in biotechnology, founded in 2017.
The company sits in the biotechnology segment, where it competes on its core product or service.
San Francisco, California, US is where the company is located.
Directory data places it at the Regulation D stage.
Its team size is recorded as 11-50 employees.
Total disclosed funding stands at about $5.9M.
| Sector | Biotechnology |
|---|---|
| Headquarters | San Francisco, California, US |
| Country | United States |
| Founded | 2017 |
| Employees | 11-50 |
| Stage | Regulation D |
| Total funding | $5,859,944 |
Website: mekonos.com
Emails and contact routes are reserved for registered members.
Create a free account
Create a free account